PTC/SB/08a (08-03)
Approved for use through 07/31/2006, OMB 0651-0/03 I
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Remove

Approved for use "mough 07/37/2006 ONIS 0851-0031
U.S. Patient and Trademank Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid ONIS control number.

	Application Number		
INFORMATION DIGGS COURT	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Berg		er
	Art Unit		
	Examiner Name		
	Attorney Docket Numb	er	72.104

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Pate of cited Docu	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1										
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.	-	Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where	
	1	20020014881	A1	2002-0	2-07	Masashi Yasu					
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	elease click the Ad	d button	$\overline{}$		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country	y Code ²	Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	or ,	vhere Rele	or Relevant	74
	1	10158266	DE		A1	2003-06-26	Robert Bosch Gmb	Н			
	2	1201958	EP		A2	2002-05-02	Delta Tooling Co.,	Ltd.			V
	3	10138123	DE		A1	2003-02-27	Robert Bosch Gmb	Н			
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add										

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Filing Date					
	First Named Inventor Berger		31			
	Art Unit					
	(Not to Submission and or or trissy	Examiner Name				
		Attorney Docket Numb	er	72.104		
	NON	PATENT LITERATURE	DOC	JMENTS	Remove	_

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

T5

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

Annlication Number

publisher, city and/or country where published.

Evaminer Cite

English language translation is attached.

Initials* No.

1								
If you wish to add	d additional non-patent literature document citation information p	lease click the Add I	outton Add					
EXAMINER SIGNATURE								
Examiner Signatu	ure	Date Considered						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a								

* See Not Code of USPTO Patent Documents 4 years USPTO.001/c MPEP 901.04. * Eater office that leaved the document by the two-later code of USPO Standard 513, * The spaces patent document, the document, the page of the region of the document process as word in their off in patent course. **Note of USPO Standard 513, **The spaces page of USPO Standard 514, **The spa

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Application Number		
INFORMATION DIGGI COURT	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor	Named Inventor Berger	
	Art Unit		
(·······	Examiner Name		
	Attorney Docket Numb	er	72.104

CERTIFICATION STATEMENT

- IC	rase see or	OF K 1.57	allu 1.50 tt	illake ule a	propriate	SCICCIOI	ıηs).				
	That cook	itom of in	formation	contained in	the inform	notion di	icalocuro	ctatament	was first	 	

	Inat each term or incompation contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.
OR	

That no item of information contained in the information disclosure statement was cited in a communication from a
foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
statement.

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Name/Print

None SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature. | Date (YYYY-MM-DD) |

Registration Number

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to leak a flour to complete, including gathering, prepaning and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burder, should be sent to the Chef information Ordice U.S. Description, to 2011 the control of the Complete Complete

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission, which may related the process and/or examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
 - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.